Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{[6-(pentyloxy)naphthalen-2-yl]sulfonyl}-D-glutamic acid is a synthetic small molecule and a derivative of D-glutamic acid, featuring a sulfonamide linkage to a substituted naphthalene ring. It is classified as an experimental compound and has not been approved for clinical use. The compound has been referenced in chemical databases such as DrugBank, ChEMBL, and PubChem but lacks detailed information on its mechanism of action or therapeutic indication. There are no reported clinical trials or approved indications for this molecule, suggesting it remains at the preclinical or early research stage[1][2][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-{[6-(pentyloxy)naphthalen-2-yl]sulfonyl}-D-glutamic acid.